huvecs (five donors pooled batch) (BioWhittaker Molecular Applications)
90
Structured Review
BioWhittaker Molecular Applications
huvecs (five donors pooled batch)
Huvecs (Five Donors Pooled Batch), supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/huvecs+(five+donors+pooled+batch)/huvecs++five+donors+pooled+batch+/pm16720756-91-0-8
Average 90 stars, based on 1 article reviews
Huvecs (Five Donors Pooled Batch), supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/huvecs+(five+donors+pooled+batch)/huvecs++five+donors+pooled+batch+/pm16720756-91-0-8
Average 90 stars, based on 1 article reviews
huvecs (five donors pooled batch) - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Incubation:Article Title: Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. Article Snippet: Angiogenesis is a promising target for the therapy of several diseases including cancer.. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A2 (TXA2) inhibitors derived from torasemide, a marketed loop diuretic with TXA2 antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay.. All drugs tested exhibited a marked affinity toward human platelet TXA2 receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA2 receptor agonist, and inhibited platelet TXA2 synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. Colorimetric Assay:Article Title: Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. Article Snippet: Angiogenesis is a promising target for the therapy of several diseases including cancer.. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A2 (TXA2) inhibitors derived from torasemide, a marketed loop diuretic with TXA2 antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay.. All drugs tested exhibited a marked affinity toward human platelet TXA2 receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA2 receptor agonist, and inhibited platelet TXA2 synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. Metabolic Labelling:Article Title: Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. Article Snippet: Angiogenesis is a promising target for the therapy of several diseases including cancer.. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A2 (TXA2) inhibitors derived from torasemide, a marketed loop diuretic with TXA2 antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay.. All drugs tested exhibited a marked affinity toward human platelet TXA2 receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA2 receptor agonist, and inhibited platelet TXA2 synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. |